ICU Medical Technologies S.L. has developed KronoSafe System®, a device that allows temporary cardiac pacing with active-fixation leads.
- Low rate of complications
- Avoid ICU admission
- Early rehabilitation
- Allow Cardiac Stimulation at home
- Short learning curve
- Easy market entry
Number of current investors: 4
ICU MEDICAL TECHNOLOGIES
ICU Medical Technologies S.L. is the Medical Device Company that has developed KronoSafe®. This System allows temporary cardiac pacing with active-fixation leads, adapting for external use the definitive pacemaker generators and electrodes. According to current projections, it will be on sale by the end of 2022.
The increased safety and effectiveness provided by KronoSafe® allows the patient to be discharged from the Intensive Care Unit, freeing up necessary beds for other critical patients. In addition, it provides the safety needed to perform temporary cardiac pacing at home.
The initial investment round will allow us to start sales at the European market, where more than 200,000 procedures per year are done.
Now is the best moment to participate in the KronoSafe® Project.
Temporary Cardiac Stimulation is a procedure performed 200,000 times a year in Europe, and more than 1,000,000 times a year worldwide.
USERS AND CUSTOMERS
Our users will be Intensive Care Physicians and Cardiologists in which we will reduce the complications of their patients using KronoSafe®.
Our customers will be the health systems, hospitals; to which we also provide financial savings: we will reduce the costs related to the treatment of complications and the hospital stay, liberating ICU beds for other patients.
INTELLECTUAL PROPERTY PROTECTION
At present, KronoSafe System® has a Spanish Patent and a favorable PCT report for all its claims. We have started the procedure to expand our KronoSafe® protection in strategic countries such as the USA, China, Canada, India, Australia, Russia and Europe.
The ICU Medical Technologies project has an Economic Viability Study carried out by an independent consultancy, supporting our projections.
Founder and Chief Executive Officer (CEO)
COO (Chief Operations Officer) & Regulatory Affairs Manager
Chief Marketing Officer
TOTAL INVESTMENT ROUND:
- Staff 55% 55%
- Production and Commercialization 27% 27%
- World Intellectual Property Protection 14% 14%
- Other expenses 4% 4%